CoreCap Advisors’s Coherus Oncology CHRS Stock Holding History

CoreCap Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.54K	Buy	2,924 +489	+20%	+$669	﹤0.01%	2342
2026 Q2	$3.41K	Sell	2,435 -37	-1%	-$60	﹤0.01%	2386
2026 Q1	$4.18K	Buy	+2,472	New	+$4.39K	﹤0.01%	2228

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

CoreCap Advisors's CHRS Position: Q3 2026 in Review

CoreCap Advisors increased its Coherus Oncology (CHRS) stake by 20% in Q3 2026, buying an estimated $669 and bringing the position to 2,924 shares worth $3.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

CoreCap Advisors first reported a position in CHRS in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.18K in Q1 2026. 7 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

CoreCap Advisors held 2,924 shares of Coherus Oncology worth $3.54K as of Q3 2026.
CoreCap Advisors bought 489 Coherus Oncology shares in Q3 2026, an estimated $669.
Coherus Oncology made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2342 holding.
CoreCap Advisors first reported a position in Coherus Oncology in Q1 2026 and has held it in 3 quarters since.
CoreCap Advisors's Coherus Oncology position peaked at $4.18K in Q1 2026.
7 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.